Navigation Links
Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology

were localized to the treatment site, with the most frequent being mild injection site pain.

Objective tumor responses, defined as 50% tumor shrinkage or complete disappearance, were observed in 12 of 39 (31%) of the lesions that were targeted for observation. Of these observed lesions, seven of 18 treated tumors (38%) and five of 21 untreated tumors (24%) showed objective responses. The response of untreated tumor lesions suggests the possibility of a systemic effect of the treatment. Two subjects showed activity in untreated tumors distant from the site of administration of the therapy, including one subject showing shrinkage and disappearance of lung tumors.

"This is the third set of interim clinical data to be released this year supporting the safety and tolerability of Inovio's electroporation technology for delivering DNA immunotherapeutics in humans. The objective tumor responses observed by Vical add to a body of data suggesting that electroporation of plasmid-based immunotherapeutics can induce immune and anti-tumor responses," said Dr. Avtar Dhillon, Inovio's President and CEO. "We look forward to advancing the business opportunities that become more apparent with such results."

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly enhance the potency of such immunotherapies.

Inovio's DNA-based immunotherapy products consist of DNA plasmids and the Elgen and MedPulser DNA delivery systems. DNA plasmids are designed to express antigens that can induce an immune response specific to a cancer or infectious disease-causing organism. These plasmids are created synthetically and readily manufacture
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
Post Your Comments:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 1Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 2Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 1Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 1United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 3